Analysis of gene expression profiles in melanoma cells with acquired resistance against antineoplastic drugs

Melanoma Research

Volumn 16, Issue 2, 2006, Pages 147-155

  Györffy, Balazs ^a,b   Serra, Violeta ^a   Materna, Verena ^a   Schäfer, Reinhold ^a   Dietel, Manfred ^a   Schadendorf, Dirk ^c   Lage, Hermann ^a,d  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Drug resistance; Melanoma; MeWo

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; COMPLEMENTARY DNA; ETOPOSIDE; FOTEMUSTINE; MESSENGER RNA; VINDESINE;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL STRAIN; CONTROLLED STUDY; DNA DETERMINATION; DNA MICROARRAY; GENE CLUSTER; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN CANCER; DRUG RESISTANCE; GENETICS; IN SITU HYBRIDIZATION; MELANOMA; TUMOR CELL LINE;

CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IN SITU HYBRIDIZATION; MELANOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 33745912785     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cmr.0000215037.23188.58     Document Type: Article

References (28)

1. Stewart BW, Kleihues P, editors. World cancer report. Lyon: IARC Press; 2003. pp. 253-256.
2. McGovern VJ, Balch CM, Wilton GWE. Cutaneous melanoma: clinical management and treatment results worldwide. Philadelphia: J.B. Lippincott; 1985. pp. 29-42.
3. Barth A, Morton DL. The role of adjuvant therapy in melanoma management. Cancer 1995; 75:726-734.
4. Ho RC. Medical management of stage IV malignant melanoma. Cancer 1995; 75:735-741.
5. Middleton MR, Lorigan P, Owen J, Ashcroft L, Lee SM, Harper P, et al. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 2000; 82:1158-1162.
6. Garbe C. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res 1993; 3:291-299.
7. Schadendorf D, Worm M, Algermissen B, Kohlmus CM, Czarnetzki BM. Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity. Cancer 1994; 73:103-108.
8. Serrone L, Hersey P. The chemoresistance of human malignant melanoma: an update. Melanoma Res 1999; 9:51-58.
9. Helmbach H, Rossmann E, Kern MA, Schadendorf D. Drug resistance in human melanoma. Int J Cancer 2001; 93:617-622.
10. Kern MA, Helmbach H, Artuc M, Karmann D, Jurgovsky K, Schadendorf D. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression. Anticancer Res 1997; 17:4359-4370.
11. 6- methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance. Int J Cancer 1999; 80:744-750.
12. Lage H, Helmbach H, Dietel M, Schadendorf D. Modulation of DNA topoisomerase II activity and expression in melanoma cells with acquired drug resistance. Br J Cancer 2000; 82:488-491.
13. Rünger TM, Emmert S, Schadendorf D, Diem C, Epe B, Hellfritsch D. Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide. J Invest Dermatol 2000; 114:34-39.
14. Christmann M, Pick M, Lage H, Schadendorf D, Kaina B. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int J Cancer 2001; 92:123-129.
15. Lage H, Helmbach H, Grottke C, Dietel M, Schadendorf D. DFNA5 (ICERE-1) contributes to acquired etoposide resistance in melanoma cells. FEBS Lett 2001; 494:54-59.
16. Helmbach H, Kern MA, Rossmann E, Renz K, Kissel C, Gschwendt B, et al. Drug resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency. J Invest Dermatol 2002; 118:923-932.
17. Liedert B, Materna V, Schadendorf D, Thomale J, Lage H. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. J Invest Dermatol 2003; 121:172-176.
18. Grottke C, Mantwill K, Dietel M, Schadendorf D, Lage H. Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs. Int J Cancer 2000; 88:535-546.
19. Wittig R, Messung M, Will RD, Mollenhauer J, Salowsky R, Munstermann E, et al. Candidate genes for cross-resistance against DNA-damaging drugs. Cancer Res 2002; 62:6698-6705.
20. Sinha P, Kohl S, Fischer J, Hütter G, Kern M, Köttgen E, et al. Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis 2000; 21:3048-3057.
21. Sinha P, Poland J, Kohl S, Schnölzer M, Helmbach H, Hütter G, et al. Study of the development of chemoresistance in melanoma cell lines using proteome analysis. Electrophoresis 2003; 24:2386-2404.
22. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
23. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403:503-511.
24. Fogh J, Bean MA, Brüggen J, Fogh H, Fogh JM, Hammar SP, et al. Comparison of a human tumor cell line before and after growth in the nude mouse. In: Fogh J, Giovanella B, editors. The nude mouse in experimental and clinical research. New York: Academic Press; 1978. pp. 215-234.
25. Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics 2002; 18:207-208.
26. Materna V, Liedert B, Thomale J, Lage H. Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells. Int J Cancer 2005; 115:393-402.
27. Nieth C, Priebsch A, Stege A, Lage H. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett 2003; 545:144-150.
28. Soong R, Beyser K, Basten O, Kalbe A, Rueschoff J, Tabiti K. Quantitative reverse transcription-polymerase chain reaction detection of cytokeratin 20 in noncolorectal lymph nodes. Clin Cancer Res 2001; 7:3423-3429.